Role of Hippo Pathway Dysregulation from Gastrointestinal Premalignant Lesions to Cancer

Overview

Journal J Transl Med

Publisher Biomed Central

Specialties Biomedical Engineering
General Medicine

Date 2024 Feb 29

PMID 38424512

Authors

Giulia Schiavoni

Beatrice Messina

Stefano Scalera

Lorenzo Memeo

Cristina Colarossi

Marzia Mare

Giovanni Blandino

Gennaro Ciliberto

Giulia Bon

Marcello Maugeri-Sacca

Affiliations

Soon will be listed here.

Abstract

Background: First identified in Drosophila melanogaster, the Hippo pathway is considered a major regulatory cascade controlling tissue homeostasis and organ development. Hippo signaling components include kinases whose activity regulates YAP and TAZ final effectors. In response to upstream stimuli, YAP and TAZ control transcriptional programs involved in cell proliferation, cytoskeletal reorganization and stemness.

Main Text: While fine tuning of Hippo cascade components is essential for maintaining the balance between proliferative and non-proliferative signals, pathway signaling is frequently dysregulated in gastrointestinal cancers. Also, YAP/TAZ aberrant activation has been described in conditions characterized by chronic inflammation that precede cancer development, suggesting a role of Hippo effectors in triggering carcinogenesis. In this review, we summarize the architecture of the Hippo pathway and discuss the involvement of signaling cascade unbalances in premalignant lesions of the gastrointestinal tract, providing a focus on the underlying molecular mechanisms.

Conclusions: The biology of premalignant Hippo signaling dysregulation needs further investigation in order to elucidate the evolutionary trajectories triggering cancer inititation and develop effective early therapeutic strategies targeting the Hippo/YAP pathway.

Citing Articles

miR-301a-mediated crosstalk between the Hedgehog and HIPPO/YAP signaling pathways promotes pancreatic cancer.

Qi B, Wang Y, Zhu X, Gong Y, Jin J, Wu H Cancer Biol Ther. 2025; 26(1):2457761.

PMID: 39846248 PMC: 11760222. DOI: 10.1080/15384047.2025.2457761.

Doublecortin-like kinase 1 promotes stem cell-like properties through the Hippo-YAP pathway in prostate cancer.

Jiang D, Li J, Ma H, Yan B, Lei H Int J Med Sci. 2025; 22(2):460-472.

PMID: 39781521 PMC: 11704687. DOI: 10.7150/ijms.99062.

The plasticity of epithelial cells and its potential in the induced differentiation of gastric cancer.

Yan Z, Liu Y, Yuan Y Cell Death Discov. 2024; 10(1):512.

PMID: 39719478 PMC: 11668900. DOI: 10.1038/s41420-024-02275-x.

Correction to: Role of Hippo pathway dysregulation from gastrointestinal premalignant lesions to cancer.

Schiavoni G, Messina B, Scalera S, Memeo L, Colarossi C, Mare M J Transl Med. 2024; 22(1):420.

PMID: 38702720 PMC: 11067124. DOI: 10.1186/s12967-024-05161-3.

References

Piccolo S, Cordenonsi M, Dupont S . Molecular pathways: YAP and TAZ take center stage in organ growth and tumorigenesis. Clin Cancer Res. 2013; 19(18):4925-30. DOI: 10.1158/1078-0432.CCR-12-3172. View

Justice R, Zilian O, Woods D, Noll M, Bryant P . The Drosophila tumor suppressor gene warts encodes a homolog of human myotonic dystrophy kinase and is required for the control of cell shape and proliferation. Genes Dev. 1995; 9(5):534-46. DOI: 10.1101/gad.9.5.534. View

Pantalacci S, Tapon N, Leopold P . The Salvador partner Hippo promotes apoptosis and cell-cycle exit in Drosophila. Nat Cell Biol. 2003; 5(10):921-7. DOI: 10.1038/ncb1051. View

Harvey K, Tapon N . The Salvador-Warts-Hippo pathway - an emerging tumour-suppressor network. Nat Rev Cancer. 2007; 7(3):182-91. DOI: 10.1038/nrc2070. View

Lamar J, Stern P, Liu H, Schindler J, Jiang Z, Hynes R . The Hippo pathway target, YAP, promotes metastasis through its TEAD-interaction domain. Proc Natl Acad Sci U S A. 2012; 109(37):E2441-50. PMC: 3443162. DOI: 10.1073/pnas.1212021109. View

Zanconato F, Cordenonsi M, Piccolo S . YAP/TAZ at the Roots of Cancer. Cancer Cell. 2016; 29(6):783-803. PMC: 6186419. DOI: 10.1016/j.ccell.2016.05.005. View

Maugeri-Sacca M, De Maria R . The Hippo pathway in normal development and cancer. Pharmacol Ther. 2018; 186:60-72. DOI: 10.1016/j.pharmthera.2017.12.011. View

Cordenonsi M, Zanconato F, Azzolin L, Forcato M, Rosato A, Frasson C . The Hippo transducer TAZ confers cancer stem cell-related traits on breast cancer cells. Cell. 2011; 147(4):759-72. DOI: 10.1016/j.cell.2011.09.048. View

Zeng R, Dong J . The Hippo Signaling Pathway in Drug Resistance in Cancer. Cancers (Basel). 2021; 13(2). PMC: 7830227. DOI: 10.3390/cancers13020318. View

10.

Arnold M, Abnet C, Neale R, Vignat J, Giovannucci E, McGlynn K . Global Burden of 5 Major Types of Gastrointestinal Cancer. Gastroenterology. 2020; 159(1):335-349.e15. PMC: 8630546. DOI: 10.1053/j.gastro.2020.02.068. View

11.

Dong J, Feldmann G, Huang J, Wu S, Zhang N, Comerford S . Elucidation of a universal size-control mechanism in Drosophila and mammals. Cell. 2007; 130(6):1120-33. PMC: 2666353. DOI: 10.1016/j.cell.2007.07.019. View

12.

Messina B, Lo Sardo F, Scalera S, Memeo L, Colarossi C, Mare M . Hippo pathway dysregulation in gastric cancer: from Helicobacter pylori infection to tumor promotion and progression. Cell Death Dis. 2023; 14(1):21. PMC: 9837097. DOI: 10.1038/s41419-023-05568-8. View

13.

Perra A, Kowalik M, Ghiso E, Ledda-Columbano G, Di Tommaso L, Angioni M . YAP activation is an early event and a potential therapeutic target in liver cancer development. J Hepatol. 2014; 61(5):1088-96. DOI: 10.1016/j.jhep.2014.06.033. View

14.

Sun M, Sun Y, Feng Z, Kang X, Yang W, Wang Y . New insights into the Hippo/YAP pathway in idiopathic pulmonary fibrosis. Pharmacol Res. 2021; 169:105635. DOI: 10.1016/j.phrs.2021.105635. View

15.

Ma S, Guan K . Polycystic kidney disease: a Hippo connection. Genes Dev. 2018; 32(11-12):737-739. PMC: 6049516. DOI: 10.1101/gad.316570.118. View

16.

Russell J, Camargo F . Hippo signalling in the liver: role in development, regeneration and disease. Nat Rev Gastroenterol Hepatol. 2022; 19(5):297-312. PMC: 9199961. DOI: 10.1038/s41575-021-00571-w. View

17.

Cai J, Zhang N, Zheng Y, de Wilde R, Maitra A, Pan D . The Hippo signaling pathway restricts the oncogenic potential of an intestinal regeneration program. Genes Dev. 2010; 24(21):2383-8. PMC: 2964748. DOI: 10.1101/gad.1978810. View

18.

Taniguchi K, Wu L, Grivennikov S, de Jong P, Lian I, Yu F . A gp130-Src-YAP module links inflammation to epithelial regeneration. Nature. 2015; 519(7541):57-62. PMC: 4447318. DOI: 10.1038/nature14228. View

19.

Hong L, Li X, Zhou D, Geng J, Chen L . Role of Hippo signaling in regulating immunity. Cell Mol Immunol. 2018; 15(12):1003-1009. PMC: 6269503. DOI: 10.1038/s41423-018-0007-1. View

20.

Dupont S, Morsut L, Aragona M, Enzo E, Giulitti S, Cordenonsi M . Role of YAP/TAZ in mechanotransduction. Nature. 2011; 474(7350):179-83. DOI: 10.1038/nature10137. View